Tenapanor (0.15, 0.5 mg/kg; p.o.) reduces passive paracellular phosphate absorption in rats[1].
Tenapanor (0.15 mg/kg; p.o.; twice-daily for 11 consecutive days) increases the reduction in urinary phosphorus excretion in rats[2].
| Animal Model: | Rats (intestinal loop model)[1] |
| Dosage: | 0.15, 0.5 mg/kg |
| Administration: | P.o. |
| Result: | Reduced passive paracellular phosphate absorption by reduced urinary phosphate and sodium excretion after the high-phosphate meal and increased sodium and phosphate delivery to the cecum. |
| Animal Model: | 8 weeks, 250 g male Sprague–Dawley rats[2] |
| Dosage: | 0.15 mg/kg in combination with sevelamer (0%, 0.75%, 1.5%, and 3% (wt/wt)) |
| Administration: | Oral gavage; twice-daily for 11 consecutive days |
| Result: | Significantly augmented the reduction in urinary phosphorus excretion. |
